Study #2020-0054
A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraga
MD Anderson Study Status
Not Accepting
Treatment Agent
EO2401, Nivolumab
Description
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Study phase:
Physician name:
Aung Naing
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-923-4997
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.